ANI Pharmaceuticals ANIP Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's accounts receivable?
- ANI Pharmaceuticals (ANIP) reported accounts receivable of $255.43M in Q1 2026.
- How has ANI Pharmaceuticals's accounts receivable changed year-over-year?
- ANI Pharmaceuticals's accounts receivable increased by 15.9% year-over-year, from $220.33M to $255.43M.
- What is the long-term trend for ANI Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's accounts receivable has grown at a 24.0% compound annual growth rate (CAGR), from $95.79M to $281.08M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.